Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 14 Nov 2022 |
| Genmab to Present at Jefferies London Healthcare Conference | 10 Nov 2022 |
| Genmab Announces Financial Results for the First Nine Months of 2022 | 9 Nov 2022 |
| Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH) | 3 Nov 2022 |
| Genmab Improves Its 2022 Financial Guidance | 3 Nov 2022 |